Some researchers used electrochemical luminescence immunoassay (ECLIA) to measure the level of cerebrospinal fluid NSE in AD patients and healthy subjects, and the results showed that the level of cerebrospinal fluid NSE in AD patients was significantly higher than that in healthy subjects. This evidence concerns the gene ENO2 and Alzheimer disease.